Peer Review History

Original SubmissionMay 13, 2020
Decision Letter - Michael Bader, Editor

PONE-D-20-14270

Expression characteristics and regulatory mechanism of Apela gene in liver of chicken (Gallus gallus)

PLOS ONE

Dear Dr. Liu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 20 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Michael Bader

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this manuscript Tan et al shew that the expression pattern of apela at different tissues at two time points and found that apela was expressed highly in liver et al. Finally Tan et al wanted to prove the 17β-estradiol induce the expression of apela to involves in liver lipid metabolism. This work is inteseting but far more work is needed to confirm the conclusion (experiments and discussion).

1, why liver et al while not ovary or another related tissues displayed high expression of apela? discussion was needed here.

2, the authors used different ER inhibitor to evaluate which receptor was in the cascade to control apela expression, it looks reasonable. While we suggest the author to check the expression of the different receptors in different tissues at the two time points, that is benefit to get the conclusion.

3, the authors wanted to show apela mediates ER to regulate liver lipid metablism, and used the word "likely", but I suggest to do more work to confirm it since it is easy to do. If not we suggest not to discuss this point in the manuscript. You know there is a big gap here.

4, the disscussion only list the experiment again while not discuss the question about this study. In addition, we suggested the authors discuss the study within a deep way.

Reviewer #2: The authors reported the cloning of Apela/Elabela gene in chicken, its expression across the tissues and inducible expression in the liver of hens or hepatocytes at the peak-laying stage or by 17beta-estradiol treatment. They concluded that Apela may be involved in liver lipid metabolism of laying chicken through estrogen-induced regulation. The cloning of Apela in chicken was reported 2 years ago, in which Apelin and Apelin receptor were also well characterized (PMID: 30631305). What’s new here is that inducible expression of Apela in the liver and its correlation with ApoVLDLII expression.

Comments

1. Apelin (Apln) and Apelin receptor (Aplnr) should be examined in the liver of hens and hepatocytes at the peak-laying stage and by 17beta-estradiol treatment, respectively.

2. A key question is whether Apela gene in chicken express the peptide. Since the 3’UTR of Apela mRNA has regulatory roles on gene expression depending on species (PMID: 25936916), it would be possible that chick Apela may only serve as a non-coding RNA.

3. It should be clarified whether Apela peptide indeed regulate lipid metabolism in the liver of laying chicken. It is also possible that Apela may regulate lipid metabolism in other organs in endocrine manner. These points should be investigated experimentally.

4. Compared with induction of ApoVLDLII, increase of Apela expression is modest at the peak-laying stage. Down-regulation of Apela expression in pancreas is more robust. This is also needed to examine more carefully together with expression of Apln and Aplnr.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Dear Dr. Bader,

We thank both you and reviewers for your suggestions and comments on our manuscript entitled “Expression characteristics and regulatory mechanism of Apela gene in liver of chicken (Gallus gallus)” (ID: PONE-D-20-14270). We have amended our manuscript accordingly and marked the revised portion in red. The point by point responses to the comments and suggestions raised by reviewers are listed below. We hope that the revised manuscript is acceptable for publication in your Journal PLOS ONE.

Should you have any further questions, please don’t hesitate to contact us.

Yours sincerely,

Xiaojun Liu & Wenbo Tan, on the behalf of all the co-authors

College of Animal Science and Veterinary Medicine

Henan Agricultural University

Zhengzhou 450046

China

Tel: 0086-371-63555618

Fax: 0086-371-63558180

Email: xjliu2008@hotmail.com

603679737@qq.com

The point by point responses to the comments raised by reviewers

Reviewer #1: In this manuscript Tan et al shew that the expression pattern of apela at different tissues at two time points and found that apela was expressed highly in liver et al. Finally Tan et al wanted to prove the 17β-estradiol induce the expression of apela to involves in liver lipid metabolism. This work is inteseting but far more work is needed to confirm the conclusion (experiments and discussion).

Author response: Thank you very much for your comments on the work. To the best of our knowledge, this is the first time to report the expression characteristics and regulatory mechanism of Apela gene in liver of chicken. We have carefully amended our manuscript according to your comments and suggestions, and hope the revised version is satisfied.

1, why liver et al while not ovary or another related tissues displayed high expression of apela? discussion was needed here.

Author response: Thank you very much for your suggestion. According to the studies on apela expression so far, expression patterns of apela are various in different species, which may associate with its biological functions. In Zebrafish, apela is expressed predominantly in the testes and weakly in other tissues including the intestine, brain and heart. In human beings, expression of apela is associated with pre-implantation human development, and restricted to a few tissues, including cardiovascular tissues and two endocrine organs, the kidneys and placenta in the adult. In rodents, expression of apela can be detected in the stage of zygotic transcription, and peaked at the blastocyst stage. As for chicken, both our study and other previous study showed that apela is mainly expressed in liver and other two endocrine organs kidney and pancreas. We have amended our manuscript by adding the above information with corresponding references. Please see details in the revised manuscripts in line 375-381, line 382-388 and line 393-394.

2, the authors used different ER inhibitor to evaluate which receptor was in the cascade to control apela expression, it looks reasonable. While we suggest the author to check the expression of the different receptors in different tissues at the two time points, that is benefit to get the conclusion.

Author response: Thank you very much for your valuable suggestions. Accordingly, we checked the expression levels of ER α and ER β in the liver of pre-laying hens (20 weeks old) and peak-laying hens (30 weeks old), and found that the expression levels of ER α and ER β increased with sexual maturation. It should be the true because, in general, the estrogen level of hens rises significantly during the egg-laying period, and estrogen acts on many of genes involved in hepatic metabolisms, e.g. lipid and fatty acid metabolism, by interaction with either ER α or ER β, and certainly other pathways. We have added the results in line 303-306 and 402-411 of text and Supplement Fig. 3 in the revised manuscript.

3, the authors wanted to show apela mediates ER to regulate liver lipid metablism, and used the word "likely", but I suggest to do more work to confirm it since it is easy to do. If not we suggest not to discuss this point in the manuscript. You know there is a big gap here.

Author response: Thank you very much for your valuable suggestions. To make the description more precise, we have removed all the parts related the "likely" in the text of the revised manuscript.

4, the discussion only list the experiment again while not discuss the question about this study. In addition, we suggested the authors discuss the study within a deep way.

Author response: Thank you very much for your comments. We have carefully amended the discussion section of our manuscript by adding more information about the evolution and function of the gene in details on line 371-374, 375-381, 382-388, and 393-394. We also added the discussion about the mechanism of estrogen regulating apela expression in details in line 402-411. In addition, we discussed the coding ability of Apela in details as well in line 426-437.

Reviewer #2: The authors reported the cloning of Apela/Elabela gene in chicken, its expression across the tissues and inducible expression in the liver of hens or hepatocytes at the peak-laying stage or by 17beta-estradiol treatment. They concluded that Apela may be involved in liver lipid metabolism of laying chicken through estrogen-induced regulation. The cloning of Apela in chicken was reported 2 years ago, in which Apelin and Apelin receptor were also well characterized (PMID: 30631305). What’s new here is that inducible expression of Apela in the liver and its correlation with ApoVLDLII expression.

Author response: Thank you very much for your comments on our work. Most of the work presented in the manuscript was being done before 2017 by a master student, who obtained her degree on July 2017. During the preparation of the manuscript, many related research papers published. Some of our work lost their novelty. Therefore, we focused only on “expression characteristics and regulatory mechanism of Apela gene in liver of chicken” in the manuscript. The related results are added in line 109.

Comments

1. Apelin (Apln) and Apelin receptor (Aplnr) should be examined in the liver of hens and hepatocytes at the peak-laying stage and by 17beta-estradiol treatment, respectively.

Author response: Thank you very much for your suggestion. We have examined the expression of Apelin (Apln) and Apelin receptor in the liver of hens at the peak-laying stage and hepatocytes treated by 17beta-estradiol, respectively. The related results are added in line 256, 266-268, 292-293 and Supplementary Fig. 1 and 2.

2. A key question is whether Apela gene in chicken express the peptide. Since the 3’UTR of Apela mRNA has regulatory roles on gene expression depending on species (PMID: 25936916), it would be possible that chick Apela may only serve as a non-coding RNA.

Author response: Thank you very much for your valuable comments. We refer to the results of this paper (PMID: 25936916) and analyzed 3’UTR of chicken Apela mRNA. We found that Apela mRNA has regulatory roles on gene expression depending on species.The 3’UTRs are of very different lengths and show a low homology between these two orthologous genes, which implied the 3'UTR of Apela gene in chicken and mouse may play different roles. Of course, it requires further experimental verification. The result is added in line 92-95, 426-437 and Supplement Fig. 4 in the revised manuscript.

3. It should be clarified whether Apela peptide indeed regulate lipid metabolism in the liver of laying chicken. It is also possible that Apela may regulate lipid metabolism in other organs in endocrine manner. These points should be investigated experimentally.

Author response: Thanks for your comments and suggestions. Indeed, we don’t have direct solid evidences to confirm that Apela peptide regulates lipid metabolism in the liver of laying chicken or other organs in endocrine manners. Since the manuscript focuses on “expression characteristics and regulatory mechanism of Apela gene in liver of chicken”, we have removed the related statements in the revised manuscript as suggested by other reviewer.

4. Compared with induction of ApoVLDLII, increase of Apela expression is modest at the peak-laying stage. Down-regulation of Apela expression in pancreas is more robust. This is also needed to examine more carefully together with expression of Apln and Aplnr.

Author response: Thank you very much for your valuable comments. The expression of Apela in pancreas did appear significantly changes, we will focus on the role of apela in pancreas in future research, and carry out in-depth study on its biological function. The relevant description is added in line 402-411.

Attachments
Attachment
Submitted filename: Response to review.doc
Decision Letter - Michael Bader, Editor

Expression characteristics and regulatory mechanism of Apela gene in liver of chicken (Gallus gallus)

PONE-D-20-14270R1

Dear Dr. Liu,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. One reviewer did not like your answer to the question on the possible non-coding function of the APELA-mRNA you describe. But you mention the publication (ref 19) about noncoding functions of the mRNA in human ESCs and the paper (ref 42) showing that it also produces a peptide in the same cells, which is sufficient to address this issue in my opinion.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Michael Bader

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: No

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Your group found that the interesting expression pattern of apela/aplnr in chicken, and checked tdhe relationship between them and ER signaling, it is intersting and useful for the futher study. while the function of apela in liver metabolism need far more work to address.

Reviewer #2: Apela is a gene encoding a peptide ligand for Apelin receptor, but the authors did not clarify whether their identified gene is Apela or related pseudogene or non-coding RNA. The authors did not address the comments raised by this reviewer experimentally.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Sizhou Huang

Reviewer #2: No

Formally Accepted
Acceptance Letter - Michael Bader, Editor

PONE-D-20-14270R1

Expression characteristics and regulatory mechanism of Apela gene in liver of chicken (Gallus gallus)

Dear Dr. Liu:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Michael Bader

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .